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Abstract
Background:  Physicians' perspectives regarding hepatitis C shape their approach to patient
management. We used utility analysis to evaluate physicians' perceptions of hepatitis C-related
health states (HS) and their threshold to recommend treatment.
Methods:  A written questionnaire was administered to practicing physicians. They were asked to
rate hepatitis C health states on a visual analog scale ranging from 0% (death) to 100% (health
without hepatitis C). Physicians then judged quality of life associated with the side effects of antiviral
therapy for hepatitis C and indicated the sustained virological response rate that they would
require to recommend treatment.
Results:  One hundred and thirteen physicians from five states were included. Median utility
ratings for hepatitis C health states declined significantly with increasing severity of symptoms: HS1-
No Symptoms, No Cirrhosis (88%; 12% reduction from good health), HS2-Mild Symptoms, No
Cirrhosis (66%), HS3-Moderate Symptoms, No Cirrhosis (49%), HS4-Mild Symptoms, Cirrhosis
(40%), HS5-Severe Symptoms, Cirrhosis (18%) [p < 0.001]. The median rating for life with side
effects of antiviral therapy was 47%, suggesting a 53% reduction from good health. That was similar
to the utility value for HS3-Moderate Symptoms, No Cirrhosis. The median threshold value for
recommending treatment was a sustained response rate of 60%.
Conclusions:  1) Physicians' utility ratings for hepatitis C health states were inversely related to
the severity of disease manifestations described. 2) Physicians viewed side effects of therapy
unfavorably and indicated that on average, they would require a 60% sustained response rate
before recommending treatment, which far exceeds the efficacy of current antiviral therapy for
hepatitis C in the majority of patients.
Background
Chronic hepatitis C virus (HCV) infection is a slowly pro-
gressive disease that affects approximately 2.7 million
persons in the United States [1]. Most persons with hep-
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atitis C are asymptomatic, although some experience fa-
tigue or other nonspecific symptoms [2,3]. The minority
progress to cirrhosis, liver cancer, or liver failure [4–6].
Both physicians and patients must weigh the immediate
harm associated with treatment for HCV including side
effects and cost of therapy against potential future bene-
fits when making treatment decisions. Interferon and
ribavirin cause a number of adverse effects including fa-
tigue, flu-like symptoms, insomnia, depression, cough,
and cytopenia [7–9]. The cost of therapy is approximate-
ly $1,000 per month with additional charges for labora-
tory testing and physician's visits. On the other hand, a
sustained response to therapy is associated with persist-
ently undetectable HCV RNA, improved liver histology,
and gains in health-related quality of life [10–12].
Limited information is available about physicians' per-
ceptions of quality of life with hepatitis C. Physicians'
perspectives on HCV and its treatment may influence the
advice that they give to their patients about the disease.
In the current study, we used utility analysis to evaluate
physicians' perspectives about hepatitis C and its thera-
py. Utility analysis provides a means to quantify prefer-
ence values about disease states [13,14]. The aims of the
study were: 1) to assess whether physicians could pro-
vide utilities for hepatitis C health state constructs using
visual analog scales, 2) to quantify physicians' judgments
about various hepatitis C health states, and 3) to assess
physicians' thresholds for recommending treatment.
Methods
Subjects and study instrument
Participants consisted of a convenience sample of 113
physicians from Illinois, Iowa, South Carolina, Indiana,
and Michigan. Physicians were surveyed when they at-
tended continuing medical education lectures in Gastro-
enterology given in 1999. The questionnaire was
administered using a paper and pencil format and was
completed before the lecture. Demographic information
included gender, race, education, and specialty. Partici-
pants were asked if they treated patients with Hepatitis
C. Five hepatitis C health states (HS) were described
ranging from HS1-No Symptoms, No Cirrhosis to HS5-
Severe Symptoms, Cirrhosis (Table 1). The descriptions
of the hepatitis C health states were developed based on
the findings of our previous study of symptoms in pa-
tients with HCV [3] and on a consensus of a group of
hepatologists experienced in managing patients with
hepatitis C. The description of the side effects of treat-
ment was based on published accounts of the adverse ef-
fects of interferon and ribavirin [7–9,15].
Physicians rated hepatitis C health states using a visual
analog scale where 0% represented death and 100% cor-
responded to life without hepatitis C. We designated life
without hepatitis C as the highest preference value and
assessed preferences for the health state hepatitis C with
No Symptoms, No cirrhosis because the psychological
impact of having a disease can effect health status in the
absence of physical symptoms. Physicians also rated side
effects of antiviral therapy for hepatitis C on a visual an-
alog scale. Finally, participating physicians provided
their threshold for recommending antiviral therapy.
That is, the sustained virologic response rate that they
would require before they would recommend treatment
to their patients.
Statistical analysis
Preference values for hepatitis C health states were com-
pared using the Kruskal-Wallis test. The Mann-Whitney
U test was used to evaluate the relationship between cat-
egorical demographic variables and physicians' prefer-
ence values. The relationship between continuous
demographic variables and preference values was as-
sessed by the Spearman test. This test also was used to
evaluate for an association between preference values for
hepatitis C health states, ratings of side effects of antivi-
ral therapy, and treatment threshold.
Results
Demographic data for the participating physicians are
presented in Table 2. The majority was primary care phy-
sicians (81%), including Internists and Family Practi-
tioners.
Physicians' preference values for the hepatitis C health
states are shown in Figure 1. Utility values decreased as
health state severity increased (p < 0.001). The median
preference value for HS1-No Symptoms, No Cirrhosis
was 88% (interquartile range 75%–95%) corresponding
to a 12% reduction from life without hepatitis C. In con-
trast the median preference value for HS5-Severe Symp-
toms, Cirrhosis was only 18% (interquartile range 8%–
30%).
The median preference value for life with the side effects
of antiviral therapy was 47% (interquartile range 23%–
55%). That is, physicians felt that side effects were asso-
ciated with a 53% reduction from good health. After con-
sidering the HCV health states and the side effects of
therapy, physicians indicated that they would require a
median of a 60% sustained response rate (interquartile
range 40%–80%) before recommending treatment. Only
13% of participating physicians would accept the 30% re-
sponse rate offered by current antiviral therapy for pa-
tients with HCV genotype 1 disease (Figure 2).
Health state utility values did not vary significantly with
physicians' age, gender, race, specialty or whether they
treated hepatitis C. Ratings of side effects and thresholdsBMC Gastroenterology (2001) 1:6 http://www.biomedcentral.com/1471-230X/1/6
for recommending treatment were similar across the de-
mographic variables. There were no significant correla-
tions between preference values for hepatitis C health
states, ratings of side effects of therapy, and treatment
thresholds.
Discussion
In the current study, we developed and evaluated de-
scriptions of hepatitis C health states and side effects of
antiviral therapy. We found that physicians understood
these descriptions and were able to provide utility
Table 1: Descriptions of hepatitis C health states and treatment side effects.
Health State 1
Hepatitis C with No Symptoms, No Cirrhosis
• No physical symptoms
• May transmit to sexual partner
• May develop cirrhosis
Health State 2
Hepatitis C with Mild Symptoms, No Cirrhosis
• Sometimes do not feel rested
• Tire more easily than usual
• May transmit to sexual partner
• May develop cirrhosis
Health State 3
Hepatitis C with Moderate Symptoms,
No Cirrhosis
• Frequently do not feel rested
• Tire easily
• Limited in physical activities
• May transmit to sexual partner
• May develop cirrhosis
Health State 4
Hepatitis C with Mild Symptoms, Cirrhosis
• Sometimes do not feel rested
• Tire more easily than usual
• May transmit to sexual partner
• Have cirrhosis
• May get liver cancer
• May get liver failure
Health State 5
Hepatitis C with Severe Symptoms, Cirrhosis
• Sleep is disturbed
•U s u a l l y  f e e l  t i r e d
• Limited in physical activities including work
• Little interest in sex
• Have cirrhosis
• May get liver cancer
• May need liver transplant
Treatment Side Effects
Side Effects of Treatment for Hepatitis C
• Needle sticks three times a week
• Pills twice daily
• Flu-like symptoms
• Fever, chills, nausea, headache, poor
appetite
• Tend to improve after the first 2 weeks
• Tiredness, difficulty sleeping, irritability,
difficulty concentrating
• Chance of other non-life threatening
medical problems that go away after
treatment is completed such as low blood
count, hair loss, and depressionBMC Gastroenterology (2001) 1:6 http://www.biomedcentral.com/1471-230X/1/6
assessments using a visual analog scale. Preference val-
ues declined significantly with increasing health state se-
verity supporting the validity of the health state
constructs.
Physicians felt that hepatitis C causes a dramatic reduc-
tion in health status. Even the presence of hepatitis C,
without symptoms or cirrhosis (HS 1), was judged to car-
ry a 12% decrement from life without HCV. Our findings
parallel those of a study that used the time-trade off
method to assess physicians' preference values for health
states associated with hepatitis B and HIV [16]. Interest-
ingly, the median preference value for hepatitis C with-
out symptoms in our series was between that provided
for HBV without symptoms (92%) and HIV without
symptoms (83%) in the previous study [16].
The large range of physicians' rating of treatment side ef-
fects (Figure 1) is striking and indicates that doctors'
views about the impact of side effects on health status
vary substantially. However, the side effects of antiviral
therapy were judged severely overall, with a median pref-
erence value of 47%. That is, time on therapy was felt to
be associated with a 53% reduction from good health.
The median preference value for treatment side effects
was similar to that provided for HS3-Moderate Symp-
toms, No Cirrhosis.
On average, physicians indicated that they would require
a 60% sustained response before recommending therapy
to their patients. The 60% threshold far exceeds the 30%
sustained response rate to interferon and ribavirin ther-
apy reported for patients with hepatitis C genotype 1 in-
fection [7,8]. In fact, only 13% of physicians reported a
threshold for recommending therapy of 30% or less. The
unfavorable assessment of treatment side effects report-
ed by physicians in the current study provides one expla-
nation for relatively low referral rates for hepatitis C
among primary care providers. A survey of primary care
physicians showed that only 62% refer anti-HCV positive
patients with abnormal transaminase levels to sub-spe-
cialists [17].
The lack of a significant correlation between the re-
spondents' ratings of treatment side effects and their
thresholds for recommending treatment is surprising.
We would expect clinicians to make decisions that are
consistent with their views on the harm and benefit of a
particular therapy. Our data show that a group of physi-
cians, comprised largely of primary care providers,
would require a high degree of benefit in terms of re-
sponse rate to recommend therapy for HCV, which was
not necessarily related to their perspectives on the harm
associated with treatment side effects. The absence of
such a relationship may reflect limited knowledge about
hepatitis C and response rates to therapy or precon-
ceived notions about the disease and its treatment. This
finding is particularly important because primary care
providers often decide whether to refer patients to a sub-
specialist. They also educate patients and shape their
views about new diagnoses. Continuing education for
physicians about the natural history and treatment of
Table 2: Physicians' Demographic Data
n(%)
Age (mean ± SD) 49 ± 13
Gender
Men 85 (75%)
Women 28 (25%)
Race
Caucasian 73 (66%)
Asian 31 (28%)
African American 6 (5%)
Other 1 (1%)
Degree
MD 105 (93%)
DO 8 (7%)
Specialty
Internal Medicine 60 (55%)
Family Practice 29 (26%)
Gastroenterology 10 (9%)
Emergency Medicine 2 (2%)
Other 9 (8%)
Treat Hepatitis C—yes/no 25 (22%)/87 (78%)BMC Gastroenterology (2001) 1:6 http://www.biomedcentral.com/1471-230X/1/6
hepatitis C is of key importance in helping them to pro-
vide optimal advice to their patients.
Advances in antiviral therapy for hepatitis C will affect
how physicians and patients view the issue of treatment.
Preliminary data suggest that the combination of
pegylated interferon and ribavirin will increase sus-
tained response rates to more than 50% overall, and to
greater than 40% in patients with hepatitis C genotype 1
infection [18]. Hepatologists need to understand other
physicians' perspectives on hepatitis C so that they can
adequately address their concerns about treatment is-
sues.
Further work is needed to help physicians to understand
their patients' views on hepatitis C. A recent study
showed that persons with hepatitis C preferred to expe-
dite periods of poor health, implying that they may be
more likely to proceed with antiviral therapy and its at-
tendant side effects than to delay treatment [19]. In con-
trast, the physicians in the current survey had a relatively
high threshold for recommending treatment, which
would lead them to postpone therapy in the majority of
cases. Utility analysis may have a role in facilitating joint
decision-making between physicians and patients re-
garding hepatitis C.
This study does have limitations. We studied a conven-
ience sample of physicians attending continuing medical
education lectures. The findings could be biased because
we did not collect data on response rates or on the demo-
graphic features of physicians who did not complete the
survey. Furthermore, although the study population
consisted largely of primary care providers, some sub-
specialists were included. However, the respondents do
represent a cross-section of physicians who may be in-
volved with the diagnosis of hepatitis C.
Conclusions
We have developed and evaluated health state descrip-
tions for hepatitis C. Physicians felt that hepatitis C
health states were associated with a substantial decre-
ment in health status. Physicians provided particularly
low preference values for side effects of antiviral therapy
and high thresholds for recommending treatment. How-
ever, ratings of side effects were not significantly corre-
lated with thresholds for recommending therapy,
suggesting that additional factors effect physicians views
about antiviral therapy. The use of utility analysis could
provide a basis for shared decision-making between pa-
tients and their physicians about hepatitis C.
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